Cargando…

Physicochemical properties of SARS‐CoV‐2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control

The material properties of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and its proteins are discussed. We review the viral structure, size, rigidity, lipophilicity, isoelectric point, buoyant density and centrifugation conditions, stability against pH, temperature, UV light, gam...

Descripción completa

Detalles Bibliográficos
Autores principales: Scheller, Christin, Krebs, Finja, Minkner, Robert, Astner, Isabel, Gil‐Moles, Maria, Wätzig, Hermann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283733/
https://www.ncbi.nlm.nih.gov/pubmed/32469436
http://dx.doi.org/10.1002/elps.202000121
_version_ 1783544343629398016
author Scheller, Christin
Krebs, Finja
Minkner, Robert
Astner, Isabel
Gil‐Moles, Maria
Wätzig, Hermann
author_facet Scheller, Christin
Krebs, Finja
Minkner, Robert
Astner, Isabel
Gil‐Moles, Maria
Wätzig, Hermann
author_sort Scheller, Christin
collection PubMed
description The material properties of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and its proteins are discussed. We review the viral structure, size, rigidity, lipophilicity, isoelectric point, buoyant density and centrifugation conditions, stability against pH, temperature, UV light, gamma radiation, and susceptibility to various chemical agents including solvents and detergents. Possible inactivation, downstream, and formulation conditions are given including suitable buffers and some first ideas for quality‐control methods. This information supports vaccine development and discussion with competent authorities during vaccine approval and is certainly related to drug‐targeting strategies and hygienics. Several instructive tables are given, including the pI and grand average of hydropathicity (GRAVY) of SARS‐CoV‐1 and ‐2 proteins in comparison. SARS‐CoV‐1 and SARS‐CoV‐2 are similar in many regards, so information can often be derived. Both are unusually stable, but sensitive at their lipophilic membranes. However, since seemingly small differences can have strong effects, for example, on immunologically relevant epitope settings, unevaluated knowledge transfer from SARS‐CoV‐1 to SARS‐CoV‐2 cannot be advised. Published knowledge regarding downstream processes, formulations and quality assuring methods is, as yet, limited. However, standard approaches employed for other viruses and vaccines seem to be feasible including virus inactivation, centrifugation conditions, and the use of adjuvants.
format Online
Article
Text
id pubmed-7283733
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-72837332020-06-10 Physicochemical properties of SARS‐CoV‐2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control Scheller, Christin Krebs, Finja Minkner, Robert Astner, Isabel Gil‐Moles, Maria Wätzig, Hermann Electrophoresis Fast Track The material properties of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and its proteins are discussed. We review the viral structure, size, rigidity, lipophilicity, isoelectric point, buoyant density and centrifugation conditions, stability against pH, temperature, UV light, gamma radiation, and susceptibility to various chemical agents including solvents and detergents. Possible inactivation, downstream, and formulation conditions are given including suitable buffers and some first ideas for quality‐control methods. This information supports vaccine development and discussion with competent authorities during vaccine approval and is certainly related to drug‐targeting strategies and hygienics. Several instructive tables are given, including the pI and grand average of hydropathicity (GRAVY) of SARS‐CoV‐1 and ‐2 proteins in comparison. SARS‐CoV‐1 and SARS‐CoV‐2 are similar in many regards, so information can often be derived. Both are unusually stable, but sensitive at their lipophilic membranes. However, since seemingly small differences can have strong effects, for example, on immunologically relevant epitope settings, unevaluated knowledge transfer from SARS‐CoV‐1 to SARS‐CoV‐2 cannot be advised. Published knowledge regarding downstream processes, formulations and quality assuring methods is, as yet, limited. However, standard approaches employed for other viruses and vaccines seem to be feasible including virus inactivation, centrifugation conditions, and the use of adjuvants. John Wiley and Sons Inc. 2020-06-08 2020-07 /pmc/articles/PMC7283733/ /pubmed/32469436 http://dx.doi.org/10.1002/elps.202000121 Text en © 2020 The Authors. Electrophoresis published by Wiley‐VCH Verlag GmbH & Co. KGaA https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Fast Track
Scheller, Christin
Krebs, Finja
Minkner, Robert
Astner, Isabel
Gil‐Moles, Maria
Wätzig, Hermann
Physicochemical properties of SARS‐CoV‐2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control
title Physicochemical properties of SARS‐CoV‐2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control
title_full Physicochemical properties of SARS‐CoV‐2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control
title_fullStr Physicochemical properties of SARS‐CoV‐2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control
title_full_unstemmed Physicochemical properties of SARS‐CoV‐2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control
title_short Physicochemical properties of SARS‐CoV‐2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control
title_sort physicochemical properties of sars‐cov‐2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control
topic Fast Track
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283733/
https://www.ncbi.nlm.nih.gov/pubmed/32469436
http://dx.doi.org/10.1002/elps.202000121
work_keys_str_mv AT schellerchristin physicochemicalpropertiesofsarscov2fordrugtargetingvirusinactivationandattenuationvaccineformulationandqualitycontrol
AT krebsfinja physicochemicalpropertiesofsarscov2fordrugtargetingvirusinactivationandattenuationvaccineformulationandqualitycontrol
AT minknerrobert physicochemicalpropertiesofsarscov2fordrugtargetingvirusinactivationandattenuationvaccineformulationandqualitycontrol
AT astnerisabel physicochemicalpropertiesofsarscov2fordrugtargetingvirusinactivationandattenuationvaccineformulationandqualitycontrol
AT gilmolesmaria physicochemicalpropertiesofsarscov2fordrugtargetingvirusinactivationandattenuationvaccineformulationandqualitycontrol
AT watzighermann physicochemicalpropertiesofsarscov2fordrugtargetingvirusinactivationandattenuationvaccineformulationandqualitycontrol